BG26192A3 - - Google Patents

Info

Publication number
BG26192A3
BG26192A3 BG7528686A BG2868675A BG26192A3 BG 26192 A3 BG26192 A3 BG 26192A3 BG 7528686 A BG7528686 A BG 7528686A BG 2868675 A BG2868675 A BG 2868675A BG 26192 A3 BG26192 A3 BG 26192A3
Authority
BG
Bulgaria
Application number
BG7528686A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26625843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG26192(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Priority claimed from KR1019750000261A external-priority patent/KR800001009B1/ko
Publication of BG26192A3 publication Critical patent/BG26192A3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG7528686A 1974-01-10 1975-01-09 BG26192A3 (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/432,379 US4314081A (en) 1974-01-10 1974-01-10 Arloxyphenylpropylamines
KR1019750000261A KR800001009B1 (ko) 1975-01-09 1975-01-09 아릴옥시페닐프로필 아민류의 제조방법

Publications (1)

Publication Number Publication Date
BG26192A3 true BG26192A3 (sh) 1979-02-15

Family

ID=26625843

Family Applications (3)

Application Number Title Priority Date Filing Date
BG7528686A BG26192A3 (sh) 1974-01-10 1975-01-09
BG30202A BG23212A3 (sh) 1974-01-10 1975-01-09
BG98576A BG60761B2 (bg) 1974-01-10 1994-02-25 Арилоксифенилпропиламини

Family Applications After (2)

Application Number Title Priority Date Filing Date
BG30202A BG23212A3 (sh) 1974-01-10 1975-01-09
BG98576A BG60761B2 (bg) 1974-01-10 1994-02-25 Арилоксифенилпропиламини

Country Status (23)

Country Link
US (1) US4314081A (sh)
JP (1) JPS5939418B2 (sh)
AR (3) AR205578A1 (sh)
AT (1) AT336000B (sh)
BE (1) BE824255A (sh)
BG (3) BG26192A3 (sh)
CA (1) CA1051034A (sh)
CH (1) CH609675A5 (sh)
CS (1) CS189680B2 (sh)
DD (1) DD118613A5 (sh)
DE (1) DE2500110A1 (sh)
DK (1) DK140430B (sh)
ES (1) ES433720A1 (sh)
FR (1) FR2257288B1 (sh)
GB (1) GB1493961A (sh)
IE (1) IE40346B1 (sh)
NL (2) NL181654C (sh)
PH (1) PH11652A (sh)
RO (2) RO70660A (sh)
SE (1) SE412906B (sh)
SU (1) SU1005655A3 (sh)
YU (3) YU36915B (sh)
ZA (1) ZA7532B (sh)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
JPS5283811A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Aryloxy phenyl propylamines and their salts
GB1570613A (en) * 1976-10-27 1980-07-02 Akzo Nv Biologically active tricyclic compounds and pharmaceutical compositions containing same
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
FR2455571A2 (fr) * 1979-02-15 1980-11-28 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
DE3017812A1 (de) * 1980-05-09 1981-11-12 Merck Patent Gmbh, 6100 Darmstadt Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US4430319A (en) 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4692469A (en) * 1982-09-07 1987-09-08 Ciba-Geigy Corporation Propylamine derivatives
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
US4683235A (en) * 1985-02-25 1987-07-28 Eli Lilly And Company Analgesic method
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US5149714A (en) * 1987-08-14 1992-09-22 Merrell Dow Pharmaceuticals Inc. Antidepressants
US5223540A (en) * 1987-10-22 1993-06-29 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US4876282A (en) * 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
IL89854A (en) * 1988-04-08 1994-02-27 Lilly Co Eli Phenoxypropanamines, the process for their preparation and medicinal preparations containing them
US5238959A (en) * 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1228209B (it) * 1989-01-10 1991-06-05 Grato Magnone Procedimento per la preparazione di fluoxetina cloridrato.
FI81083C (fi) * 1989-03-03 1990-09-10 Orion Yhtymae Oy Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
JPH0375680U (sh) * 1989-11-21 1991-07-30
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
US5250572A (en) * 1990-03-29 1993-10-05 Eli Lilly And Company (R)-norfluoxetine in method for occupying serotonin IC receptors
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
CA2061665C (en) * 1991-02-25 2002-04-16 Mark Mortensen Foreman Treatment of lower urinary tract disorders
US5136078A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Synthesis of b-cyanohydrins
US5136079A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Regioselective synthesis
US5320825A (en) * 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1993000811A1 (en) * 1991-07-01 1993-01-21 The General Hospital Corporation Invertebrate phenylethanolamine transporter and the use thereof
IL99316A (en) 1991-08-27 1995-03-15 Teva Pharma Production of fluoxetine and new intermediates
US5202319A (en) * 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
HU9202128D0 (en) * 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
EP0576766A1 (en) * 1992-06-29 1994-01-05 Novo Nordisk A/S Propanolamine derivatives, their preparation and use
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ES2082723B1 (es) 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
ES2101650B1 (es) * 1995-06-29 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2101654B1 (es) * 1995-07-24 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2101655B1 (es) * 1995-07-28 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2103680B1 (es) * 1995-08-03 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
ES2103681B1 (es) * 1995-09-19 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
IT1283141B1 (it) * 1996-07-11 1998-04-07 Laporte Organics Francis S P A Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
CN1154495C (zh) * 1997-11-14 2004-06-23 阿克佐诺贝尔公司 米氮平用于治疗睡眠性呼吸暂停的用途
US5936124A (en) * 1998-06-22 1999-08-10 Sepacor Inc. Fluoxetine process from benzoylpropionic acid
US6025517A (en) * 1998-08-03 2000-02-15 Sepracor Inc. Fluoxetine process from benzoylacetonitrile
WO2000041684A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company A pharmaceutical combination for the treatment of depression
FR2791345B1 (fr) * 1999-03-26 2001-05-04 Adir Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000058262A1 (en) * 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
DE60026146T2 (de) * 1999-09-03 2006-08-17 Apbi Holdings, Llc Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
US6677485B2 (en) 1999-12-17 2004-01-13 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
CZ20032380A3 (en) * 2001-03-06 2004-03-17 Eli Lilly And Company Inhibitor of monoamine uptake
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP1411912A1 (en) * 2001-07-31 2004-04-28 PHARMACIA &amp; UPJOHN COMPANY Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
CA2457385A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
CA2462903C (en) * 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
PT1455770E (pt) * 2001-11-30 2007-09-06 Lilly Co Eli Uso de inibidores de reabsorção da norepinefrina para o tratamento dos transtornos de tiques.
HUP0402619A3 (en) * 2001-12-11 2008-04-28 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
WO2003102158A2 (en) * 2002-05-31 2003-12-11 The Forsyth Institute Methods for increasing bone density
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
US6846957B2 (en) * 2002-11-22 2005-01-25 Board Of Regents, The University Of Texas System Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
EP1708717B1 (en) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetine for treatment of allergic rhinitis and asthma
NZ545494A (en) 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
JP5069907B2 (ja) * 2003-09-17 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 縮合複素環式化合物
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
AU2004305563C1 (en) 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
AU2004312059A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
WO2005094896A2 (en) * 2004-03-26 2005-10-13 Baylor University Targeted serotonin reuptake inhibitors
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1794112A4 (en) * 2004-09-27 2009-11-04 Reddys Lab Ltd Dr SYNTHESIS OF ATOMEXETINE HYDROCHLORIDE
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
EP1856087A1 (en) * 2005-03-08 2007-11-21 Teva Pharmaceutical Industries Limited Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
WO2006099433A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Pure duloxetine hydrochloride
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
CA2604759A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
US7485754B2 (en) * 2005-07-08 2009-02-03 Apotex Pharmachem Inc. Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
EP2317316A3 (en) 2005-07-08 2011-06-15 Braincells, Inc. Methods for identifying agent and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
CN101268068B (zh) * 2005-07-19 2015-12-02 阿泽范药品公司 β-内酰胺基苯丙氨酸、半胱氨酸和丝氨酸血管加压素拮抗剂
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007038253A2 (en) * 2005-09-22 2007-04-05 Teva Pharmaceutical Industries Ltd. Dnt-maleate and methods of preparation thereof
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
CN1304360C (zh) * 2005-12-12 2007-03-14 天津大学 N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
EP1844034A1 (en) * 2006-01-23 2007-10-17 Teva Pharmaceutical Industries Ltd Dnt-fumarate and methods of preparation thereof
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
PA8720801A1 (es) * 2006-03-24 2008-11-19 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento de la depresion
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007139984A2 (en) * 2006-05-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
TW200811101A (en) * 2006-07-14 2008-03-01 Ranbaxy Lab Ltd Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008026227A2 (en) * 2006-08-28 2008-03-06 Matrix Laboratories Ltd A process for the preparation of atomoxetine hydrochloride
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ITMI20061987A1 (it) 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2008062473A1 (en) * 2006-10-31 2008-05-29 Cadila Healthcare Limited Process for preparing atomoxetine hydrochloride
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP3524248A1 (en) 2007-06-21 2019-08-14 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
WO2009141833A2 (en) * 2008-04-17 2009-11-26 Ind-Swift Laboratories Limited An improved process for synthesizing highly pure atomoxetine
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
ES2728225T3 (es) 2009-02-20 2019-10-23 2 Bbb Medicines B V Sistema de administración de fármacos a base de glutatión
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8445002B2 (en) 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
WO2011027359A2 (en) 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
EP2348120B1 (en) 2009-12-30 2014-06-11 Universität Wien Enzymatic reduction of 1-phenylpropanone and derivatives thereof
PL2587919T3 (pl) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Sposoby leczenia zespołu stresu pourazowego
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US20140010883A1 (en) 2011-03-17 2014-01-09 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
US20150174083A1 (en) 2012-07-31 2015-06-25 Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine for increasing meat and milk production
US20150190352A1 (en) 2012-07-31 2015-07-09 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine in animals
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
PL3122743T3 (pl) 2014-03-28 2023-05-02 Azevan Pharmaceuticals, Inc. Kompozycje i sposoby leczenia chorób neurodegeneracyjnych
CN105777706B (zh) * 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
TW201919625A (zh) 2017-09-15 2019-06-01 美商愛治凡製藥公司 用於治療腦損傷之組合物及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683742A (en) * 1951-02-23 1954-07-13 Searle & Co Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives
ES251290A1 (es) * 1958-08-21 1960-04-01 Parke Davis & Co Un procedimiento para la producciën de alcohilaminas arilsustituidas
US3132179A (en) * 1959-08-27 1964-05-05 Sterling Drug Inc Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation
US3253040A (en) * 1962-12-10 1966-05-24 Union Carbide Corp Process for the production of primary 3-hydrocarbyloxypropylamines

Also Published As

Publication number Publication date
AR205577A1 (es) 1976-05-14
CA1051034A (en) 1979-03-20
YU3275A (en) 1982-06-18
YU37307B (en) 1984-08-31
DK688974A (sh) 1975-09-01
RO69763A (ro) 1982-02-26
FR2257288B1 (sh) 1978-07-21
YU121581A (en) 1983-04-27
DE2500110C2 (sh) 1987-06-11
AU7683674A (en) 1976-06-24
AT336000B (de) 1977-04-12
NL930108I2 (nl) 1994-08-16
BE824255A (fr) 1975-07-09
JPS5939418B2 (ja) 1984-09-22
BG60761B2 (bg) 1996-02-29
ZA7532B (en) 1976-08-25
DD118613A5 (sh) 1976-03-12
YU37308B (en) 1984-08-31
YU121481A (en) 1983-04-27
JPS50101333A (sh) 1975-08-11
FR2257288A1 (sh) 1975-08-08
IE40346L (en) 1975-07-10
CS189680B2 (en) 1979-04-30
NL930108I1 (nl) 1993-10-18
SE412906B (sv) 1980-03-24
IE40346B1 (en) 1979-05-09
GB1493961A (en) 1977-12-07
SE7500215L (sh) 1975-07-11
BG23212A3 (sh) 1977-07-12
NL181654B (nl) 1987-05-04
RO70660B (ro) 1983-08-30
ES433720A1 (es) 1976-12-01
RO70660A (ro) 1983-09-26
AR205633A1 (es) 1976-05-21
ATA10275A (de) 1976-08-15
US4314081A (en) 1982-02-02
YU36915B (en) 1984-08-31
AR205578A1 (es) 1976-05-14
PH11652A (en) 1978-05-08
DK140430B (da) 1979-08-27
DE2500110A1 (de) 1975-07-17
NL7500186A (nl) 1975-07-14
SU1005655A3 (ru) 1983-03-15
DK140430C (sh) 1980-01-21
NL181654C (nl) 1987-10-01
CH609675A5 (sh) 1979-03-15

Similar Documents

Publication Publication Date Title
FR2257288B1 (sh)
FR2270109B1 (sh)
BR7501663A (sh)
FI753002A (sh)
FR2268563B3 (sh)
JPS50142482A (sh)
FR2270225A1 (sh)
FR2260896A1 (sh)
FR2271325B3 (sh)
JPS50118162U (sh)
AU7459374A (sh)
JPS50118177A (sh)
FR2271318A1 (sh)
JPS50130426U (sh)
FR2288480B3 (sh)
JPS50120390U (sh)
JPS50139553A (sh)
CH572117A5 (sh)
CH1703874A4 (sh)
CH572167A5 (sh)
AU480143A (sh)
CH572003A5 (sh)
CH571443A5 (sh)
CH573533A5 (sh)
CH570920A5 (sh)